AstraZeneca's ATM Inhibitor, Radiation Show Encouraging Signals in Two Early Brain Cancer Trials at #AACR24 precisionmedicineonline.com/precision-onco…

Thrilled to announce our latest research just published in Nature Communications! We investigated how therapy induces therapy resistance via cell state transition and vessel co-option in glioblastoma. (1/11) nature.com/articles/s4146… #GBM #btsm #Research

Join us as we #GoGray this May for Brain Tumor Awareness Month! Show your support for those impacted by brain cancer by sharing this post and adding a photo of yourself wearing something gray. Together, let's raise awareness and stand with those who need it most. #GrayMay #BTAM

Now online in Cancer Discovery: Perivascular NOTCH3+ Stem Cells Drive #Meningioma Tumorigenesis and Resistance to Radiotherapy - by Abrar Choudhury, MD, PhD, Martha Cady, RaleighLab, and colleagues doi.org/10.1158/2159-8… UC San Francisco

The Ivy Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival for newly diagnosed glioblastoma patients. Supported by GSK, we are initiating a global, Phase 3 trial of niraparib. #ASCO24 📰: ivybraintumorcenter.org/about/newsroom…

Monday at #ASCO2024: Niraparib + XRT Phase 0/2 in Newly Diagnosed, MGMT-Unmethylated GBM OS= 20.3 months #Gliofocus Study coming in June: a global, label-enabling, Ivy Brain Tumor Center-sponsored, head-to-head Phase 3 trial in partnership with GSK

Insightful poster by Dr. Yoshie Umemura on BDTX-1535, assessing its PK, PD, & clinical responses in recurrent HGG & EGFR alterations. BDTX-1535 was well-tolerated, reaches effective concentrations in non-enhancing tumor tissue & is linked to the suppression of EGFR signaling.👏

Interesting poster from Yoshie Umemura w Ivy Brain Tumor Center on EGFR altered gliomas. Huge need for this population! #btsm #asco24 #clinicaltrials

Niraparib best in class #PARPi PK and PD properties, moving to phase III evaluation Nader Sanai #ASCO24

Promising interim survival & best in class brain penetration noted in this phase 0/2 Niraparib trial Ivy Brain Tumor Center in new GBM ⭐️ Nader Sanai will be talking more about the upcoming phase 3 trial tonight at the meet the expert session!

#ASCO24 🧠Promising new drugs for #gliomas 🗣️ Discussed Andrew Lassman 📌 N2M2/NOA: ✔️ everolimus 🎯 #mTOR ❌ No benefit atezo, asun or palbo 📌 Niraparib vs TMZ coming soon, will it beat #STUPP in unMGMT? 📌 Vebreltinib vs CT👉🏼 #GBM PTPRZ1-MET ✔️ OS HR 0.52 OncoAlert SEOM

The Ivy Brain Tumor Center at Barrow Neurological Institute announced recently a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma. Click here to learn more: ecs.page.link/R7doD

❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ GSK! We're accelerating the Gliofocus Study, a global trial comparing niraparib, a PARP1/2 inhibitor, against TMZ for newly diagnosed MGMT-unmethylated #GBM. 📰: loom.ly/ckeho64

At the Ivy Center, our dedication is to find a cure for brain cancer. On #WorldBrainTumorDay, we continue to push boundaries in brain tumor research to discover new, more effective therapies. Join us in raising awareness in the fight against brain tumors. 🌏🧠

So excited to get these data out finally. It has been such a pleasure working with Roel Verhaak Kevin Johnson and team! Key take aways - CDK4/6i treatment results in cell state change that is reproducible in vitro and no brain penetration or PD effect seen for Everolimus

Congratulations Mylan Blomquist and Nhan Tran Mayo Clinic for your paper on EGFRvIII- and STAT5-dependent sensitivity to Saracatinib treatment in #GBM mdpi.com/1422-0067/25/1…

It has been such a pleasure to work with Amy Ivy Brain Tumor Center over the last five years! She is our go to person when it comes to any data management questions! Looking forward to many more collaborative years, Amy! 👏🏻💪🏼

Next week, we will send off 38 summer research interns BarrowNeurological with a research symposium packed with student presentations, posters and a keynote speaker who has been my mentor for 25 years! I could not be more excited to welcome Dr. Huganir Rick Huganir to Barrow!

As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See pubs.acs.org/doi/10.1021/ac…, science.org/doi/10.1126/sc… and perhaps most importantly pubs.acs.org/doi/full/10.10…. Fantastic job!

So great to have three of Ivy Brain Tumor Center researchers be part of this amazing @abta community. An-Chi Tien Charuta Furey, MD and Artak Tovmasyan 👏🏻🧠